Item 7.01 Regulation FD. Nektar Therapeutics (the “Company”) is entering a quiet period beginning September 8, 2026 and continuing until the public announcement of data from the 24-week off treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.…
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory Tcell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar’s pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD.
Nektar Therapeutics (the
“Company”) is entering a quiet period beginning September 8, 2026 and continuing until the public announcement of data
from the 24-week off treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegaldesleukin in patients with
severe-to-very-severe alopecia areata. The implementation of the quiet period is consistent with the Company’s prior quiet
periods pertaining to the Phase 2b REZOLVE studies and planned data disclosures.
The information contained in Item 7.01 of this
Current Report on Form 8-K is being furnished and shall not be deemed to be “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section
and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such filing.
